AIMProteus
AKT Inhibitor Miransertib on Proteus Syndrome - Targeted therapy at NIH
Update: The AIM Proteus Trial is currently in IRB review status.
Approximate patient enrollment date for trial - Late Feb-March 2020
The NIH team is very excited about the opening of this phase 2 clinical trial. They will be hosting an Educational Information Session Webinar on Tuesday, January 21st at 11:00am eastern standard time. concerning:
Questions about the NIH AIMProteus trial email here or call.
AKT Inhibitor Miransertib on Proteus Syndrome - Targeted therapy at NIH
Update: The AIM Proteus Trial is currently in IRB review status.
Approximate patient enrollment date for trial - Late Feb-March 2020
The NIH team is very excited about the opening of this phase 2 clinical trial. They will be hosting an Educational Information Session Webinar on Tuesday, January 21st at 11:00am eastern standard time. concerning:
- trial status
- the next steps for enrollment
Questions about the NIH AIMProteus trial email here or call.
Genetic mutations can lead to many different diseases. Massachusett’s-based biotechnology company ArQule is currently conducting the MOSAIC clinical trial (Miransertib in Overgrowth Syndromes in Adults and Children) for patients who have been diagnosed with overgrowth disorders, including Proteus syndrome.
ArQule has designed the MOSAIC clinical trial to determine whether its drug candidate, miransertib, can effectively treat individuals with Proteus syndrome. Miransertib is a small molecule drug candidate that inhibits the AKT pathway. Miransertib is administered by mouth once a day. ArQule believes that by inhibiting the AKT pathway, miransertib can reduce cell overgrowth caused by the AKT1 mutation and therefore become a transformative treatment option for those individuals with Proteus syndrome and other overgrowth disorders.
Visit here to learn more. If you are interested in participating in the ArQule MOSAIC study, please email mosaicstudy@arqule.com.
ArQule has designed the MOSAIC clinical trial to determine whether its drug candidate, miransertib, can effectively treat individuals with Proteus syndrome. Miransertib is a small molecule drug candidate that inhibits the AKT pathway. Miransertib is administered by mouth once a day. ArQule believes that by inhibiting the AKT pathway, miransertib can reduce cell overgrowth caused by the AKT1 mutation and therefore become a transformative treatment option for those individuals with Proteus syndrome and other overgrowth disorders.
Visit here to learn more. If you are interested in participating in the ArQule MOSAIC study, please email mosaicstudy@arqule.com.
